Nasdaq:US$15.97 (-0.33) | HKEX:HK$25.60 (+0.15) | AIM:£2.41 (+0.1)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases, Oncology / Immunology | 22 Nov 2007

Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients

1 items
a071122